Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 12, 2023 and accepted by EDGAR at May 12, 2023, 17:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $9.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $1.3m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $186.4k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $6.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $192.2k | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 14,587,843 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $107.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $187.1k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $16.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $43.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $89.5m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $25.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $53.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $36.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-017951. Last ingested by Listed: Oct 26, 2026, 16:41 ET. Listed shows no prices and gives no investment advice.